Myriad Presents Tumor BRACAnalysis CDx(TM) Study at ESMO

Mon, 09/29/2014 -- Science News Desk

Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that its Tumor BRACAnalysis CDx™ companion diagnostic test significantly improved the detection of cancer-causing BRCA 1/2 mutations by 44 percent in women with ovarian cancer. Data from this new study were presented at the 2014 European Society for Medical Oncology (ESMO) annual meeting in Madrid, Spain.

"Several previous clinical studies have demonstrated that patients with germline or somatic BRCA 1/2 mutations respond to certain DNA-damaging medicines such as the platinum drugs," said Colin Hayward, M.D., European medical director at Myriad Genetics. "Tumor BRACAnalysis CDx also has the potential to greatly expand the number of ovarian cancer patients who may respond to treatment with PARP inhibitors."

This study evaluated 131 previously untreated patients with high-grade ovarian cancer.Blood samples were tested for germline (hereditary) BRCA mutations.Additionally, tumor samples were obtained from patients receiving surgery and were tested for both somatic (tumor) and germline BRCA mutations. The data analysis included 92 patients who completed testing for both germline and somatic mutations.The results show that the Tumor BRACAnalysis CDx test identified 28.3 percent of women with either germline or somatic BRCA 1/2 mutations.In contrast, blood germline testing only identified the 19.6 percent of patients with germline BRCA 1/2 mutations.The somatic mutations identified by Tumor BRACAnalysis CDx testing represent a 44 percent increase in the detection of cancer-causing BRCA mutations over germline testing.

Ovarian Cancer Patients with BRCA 1/2 Mutations



Tumor BRACAnalysis
CDx™ Testing (N=92)

Blood Germline
BRCA Testing (N=92)

BRCA 1 Mutations

12 germline
5 somatic

12 germline
0 somatic

BRCA 2 Mutations

6 germline
3 somatic

6 germline
0 somatic

% of mutations by

19.6% (germline)
8.7% (somatic)

19.6% (germline)

Total % of Patients



"In this study, tumor analysis identified substantially more patients with BRCA 1/2 mutations than germline blood testing alone," said Melinda Yates, Ph.D., of the MD Anderson Cancer Center in Houston, Texas and a study investigator. "The logical path forward is to use tumor testing to identify the greatest number of patients with BRCA 1/2 mutations."  

It is estimated that 65,000 women in Europe are diagnosed with ovarian cancer annually. Ovarian cancer tends to have high mortality rates and most patients face disease recurrence with limited treatment options, and Myriad is committed to working with pharmaceutical company partners to bring promising new therapies to market to improve the treatment of this lethal disease.

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision-making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website:

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra DA and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

Myriad Genetics


Disclaimer: The information provided on Science News is not intended to be a medical advice. The information on this website is also not intended to be used for diagnosis or treatment. The material provided on this site is of general informational purpose only. You may consult your physician or other qualified health provider for medical advice, diagnosis or treatment.  The inventions, discoveries, devices or products mentioned on Science News may be in planning or experimental stages and may not have approval from regulatory agencies for human or animal use.